公开(公告)号：US20080003633A1

公开(公告)日：2008-01-03

申请号：US11721652

申请日：2004-12-13

申请人： Heesup Shin ,  Soon Choi ,  Dae Kim ,  Heung Na ,  June Kim

发明人： Heesup Shin ,  Soon Choi ,  Dae Kim ,  Heung Na ,  June Kim

IPC分类号： C12Q1/02 ,  G01N33/00

CPC分类号： A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0356 ,  C07K14/705

摘要： The present invention relates to a novel use of a transgenic mouse deficient in α1G T-type calcium channel as an animal model for the study of neuropathic diseases, more precisely, a novel use of a transgenic mouse having resistance against neuropathic pain as an animal model for the development of a therapeutic agent and a treatment method for human neuropathic diseases. The transgenic mouse deficient in α1G T-type calcium channel having resistance against neuropathic pain, provided by the present invention, can be effectively used for the development of a therapeutic agent and a treatment method for human neuropathic diseases.

摘要翻译： 本发明涉及α1GT型钙通道缺陷型转基因小鼠作为神经病学研究的动物模型的新用途，更确切地说，具有抗神经性疼痛抗性的转基因小鼠作为动物模型的新用途 用于开发治疗剂和人类神经病变的治疗方法。 通过本发明提供的具有抗神经性疼痛抗性的α1GT型钙通道的转基因小鼠可以有效地用于治疗剂的开发和人类神经病变的治疗方法。

公开(公告)号：US20080060088A1

公开(公告)日：2008-03-06

申请号：US11740838

申请日：2007-04-26

申请人： Heesup Shin ,  Hae-Young Koh ,  Daesoo Kim ,  Sukchan Lee

发明人： Heesup Shin ,  Hae-Young Koh ,  Daesoo Kim ,  Sukchan Lee

IPC分类号： A61K49/00 ,  A61P43/00

CPC分类号： A61K49/0008 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0356

摘要： The present invention relates to a method for screening therapeutic drugs of schizophrenia using an animal model of the disease. More specifically, this invention relates to a screening method based on the phospholipase C β1 (PLCβ1) knockout mouse as an animal model of schizophrenia with all the major symptoms of the human disease. This knockout mouse exhibits symptoms similar to human schizophrenia such as locomotor hyperactivity, impaired prepulse inhibition of the startle response, lack of barbering and nesting behaviors, socially subordinate status, impaired learning, and lack of type II theta rhythm which has been implicated in working memory. Thus, the knockout mouse of the present invention can be useful as an animal for screening therapeutic drugs against schizophrenia.

摘要翻译： 本发明涉及使用该疾病的动物模型筛选精神分裂症的治疗药物的方法。 更具体地，本发明涉及基于磷脂酶Cβ1（PLCbeta1）敲除小鼠作为精神分裂症的动物模型的筛选方法，其具有人类疾病的所有主要症状。 这种敲除小鼠表现出类似于人类精神分裂症的症状，例如运动过度活动，惊恐反应的预脉冲抑制受损，缺乏理发和嵌套行为，社会从属状态，受损的学习以及缺乏工作记忆中的II型心律 。 因此，本发明的敲除小鼠可用作筛选针对精神分裂症的治疗药物的动物。

公开(公告)号：US07521590B2

公开(公告)日：2009-04-21

申请号：US11740838

申请日：2007-04-26

申请人： Heesup Shin ,  Hae-Young Koh ,  Daesoo Kim ,  Sukchan Lee

发明人： Heesup Shin ,  Hae-Young Koh ,  Daesoo Kim ,  Sukchan Lee

IPC分类号： G01N33/00 ,  A01K67/027 ,  A01K67/033

CPC分类号： A61K49/0008 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0356

摘要： The present invention relates to a method for screening therapeutic drugs of schizophrenia using an animal model of the disease. More specifically, this invention relates to a screening method based on the phospholipase C β1 (PLCβ1) knockout mouse as an animal model of schizophrenia with all the major symptoms of the human disease. This knockout mouse exhibits symptoms similar to human schizophrenia such as locomotor hyperactivity, impaired prepulse inhibition of the startle response, lack of barbering and nesting behaviors, socially subordinate status, impaired learning, and lack of type II theta rhythm which has been implicated in working memory. Thus, the knockout mouse of the present invention can be useful as an animal for screening therapeutic drugs against schizophrenia.

摘要翻译： 本发明涉及使用该疾病的动物模型筛选精神分裂症的治疗药物的方法。 更具体地，本发明涉及基于磷脂酶Cβ1（PLCbeta1）敲除小鼠作为精神分裂症的动物模型的筛选方法，其具有人类疾病的所有主要症状。 这种敲除小鼠表现出类似于人类精神分裂症的症状，例如运动过度活动，惊恐反应的预脉冲抑制受损，缺乏理发和嵌套行为，社会从属状态，受损的学习以及缺乏工作记忆中的II型心律 。 因此，本发明的敲除小鼠可用作筛选针对精神分裂症的治疗药物的动物。